DiaSys Diagnostic Systems GmbH

Alte Strasse 9
Holzheim,  65558

Germany
https://www.diasys-diagnostics.com/index.php?id=1141

• Booth: 4451

For 30 years, DiaSys Diagnostic Systems GmbH is focused on developing, manufacturing and commercializing system solutions for small up to mid-sized labs. In line with its strong commitment to quality, service and sustainability, DiaSys is constantly expanding its product portfolio, which comprises reagents for routine and special diagnostics, as well as fully automated clinical chemistry analyzers, semi-automated analyzers, POCT instrument and water purification systems.

 Press Releases

• New reagent for determination of Lactate Dehydrogenase (LDH) (Jan 06, 2022)

  DiaSys is pleased to announce the launch of LDH 21 FS, a new assay for determination of Lactate Dehydrogenase (LDH). Increased LDH activities are found in a variety of pathological conditions such as myocardial infarction, liver diseases, blood diseases, and cancer or muscle diseases. Increased serum LDH values are also one of the abnormal diagnostic parameters in COVID-19 patients with a severe or fatal course of disease.

  For LDH, a standardized reference method by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is available. The new LDH 21 FS uses a modified IFCC method that shows optimized performance.

  The reagent is characterized by an improved calibration and onboard stability, as well as a wide measuring range, high precision at clinical cut-offs and minimized interferences by common blood components. The ready-to-use reagent is used with fluid-stable calibrator and controls.

  The new test may be applied on all automated clinical chemical analyzers and shows good comparability with commercially available methods for the determination of LDH.

  For further information, please follow the link:
  LDH 21 FS

• New reagent for direct determination of LDL-cholesterol (Jan 06, 2022)

  DiaSys is pleased to announce the availability of LDL-c direct FS, a new homogenous assay for direct determination of LDL-cholesterol (LDL-C). LDL C is used as lipid panel parameter to estimate the risk of developing heart disease and to guide and monitor lipid-lowering therapies. Atherosclerotic cardiovascular disease (ASCVD) starts early in life, often during childhood. Studies revealed that 71% and 43% of middle-aged men and women, respectively, show evidence of subclinical atherosclerosis. Evidence from epidemiologic, genetic, and clinical intervention studies have clearly demonstrated that low-density lipoprotein (LDL) is causal in this process.

  LDL-C is often not measured directly but is instead estimated by using the Friedewald equation, which estimates LDL-C from measurements of total cholesterol (TC), triglycerides (TG), and high density lipoprotein cholesterol (HDL-C) but the method only approximates LDL-C and is subject to well-established limitations. Since the introduction of homogeneous methods at the end of the last century, these new methods have become the standard in clinical laboratories.

  The new DiaSys assay LDL-c direct FS is characterized by a wide measuring range and shows good overall precision at clinical decision limits. The ready-to-use reagent offers a long stability on board combined with low calibration frequency. The new test may be applied on all automated clinical chemical analyzers and shows good comparability with commercially available methods for the determination of LDL-cholesterol.

  The new test is available in different kit concepts. For further information, please follow the link: LDL-c direct FS

• Innovation prize for DiaSys and Fresenius University of Applied Science (Jan 06, 2022)

  The state Rhineland-Palatinate awards the 2021 Innovation Prize in the category “cooperation“ to DiaSys Diagnostic Systems GmbH along with Hochschule Fresenius, University of Applied Sciences, for developing a new procalcition (PCT) test using PETIA technology.

  In 2021, the prize, which is endowed with money, is awarded for the 33rd time. Due to the pandemic, the prize is virtually conferred by the Ministry of Economics, Transport, Agriculture and Viticulture together with the state working groups of the states chambers of industry, commerce and crafts on May 11, 2021.

  For years, DiaSys and Hochschule Fresenius – University of Applied Sciences have closely cooperated in the areas of research, development and education. Both were honored by their appointment as core members of the IFCC PCT working group. The IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) is an association for the global advancement of clinical chemistry and laboratory medicine. The PCT Working Group has established a reference procedure for quality assurance of worldwide standardized sepsis diagnostics by procalcitonin.

  The innovative reagent Procalcitonin FS, developed in cooperation with Hochschule Fresenius, is based on a further development of the PETIA technology (particle-enhanced turbidimetric immunoassay). In contrast to conventionally complex determination methods in laboratory, no special equipment is needed for handling. The PETIA method may be applied to almost all available clinical chemistry analyzers worldwide. The test guarantees precise procalcitonin results while saving both cost and time and allows early diagnosis and immediate therapeutic measures. The excellent performance characteristics of Procalcitonin FS have been confirmed in renowned medical publications since its introduction; a patent has been filed for the innovative manufacturing process of Procalcitonin FS.

  Teams of DiaSys R&D and Fresenius - University of Applied Sciences

  DiaSys is proud to belong to the most innovative companies in Rhineland-Palatinate.

  Dr. Günther Gorka, C.E.O. of DiaSys thanks all those involved in making this award and the success of Procalcitonin FS possible.

  See joint press release with Hochschule Fresenius on our website in the news sector or follow the links below for more details.

  Fresenius - University of Applied Sciences: www.hs-fresenius.de
  Innovation prize RLP 2021 - DiaSys part on YouTube: https://youtu.be/l_xrTcqa3Jw

• First training in new DiaSys Lounge in Egypt (May 04, 2022)

  Although it is not officially inaugurated yet, a first instrument training took place in our new DiaSys Lounge in Cairo.

  Seven engineers of our distributors from Libya, Albania, Djibouti and Chad received a comprehensive training for the respons®920 from our technical support team (connected online) and employees of our local partner. During 5 days, the participants learned about general installation as well as technical know-how by disassembling and assembling the analyzer. Special attention was paid to the topic of trouble shooting.

  The training was a complete success and we hope that the participants now feel well prepared for all tasks their customers may face.

  About the DiaSys Lounge

  In 2021, we opened the training center "DiaSys Lounge" in the building of our long-standing partner in Egypt, Lab Top. The aim is to provide easier access to face to face trainings outside Europe, especially for our partners from MEA and Asia. All DiaSys analyzers are installed in the lounge. Thus, there is the possibility to use the premises also as a showroom and for sales meetings. The DiaSys Lounge is a new step to provide excellent support to our distributors around the world.

 Additional Info